CytoDyn to Hold Investment Community Conference Call on December 17, 2019
VANCOUVER, Washington, Dec. 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will host an investment community conference call to provide an update on the Company.
Date: Tuesday, December 17, 2019
Time: 4:00 p.m. ET / 1:00 p.m. PT
Dial In: 877-407-2986 U.S. and Canada 201-378-4916 International
A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:
A replay of the conference call will be available until January 16, 2020. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international) and enter conference identification number 13695017.
LifeSci Public Relations
Nader Pourhassan, Ph.D.
President & CEO
Released December 11, 2019